Helix BioPharma Corp. Appoints Jack Kay as Chairman of the Board andProfessor Kazimierz Roszkowski-Sliz as European Medical Director
Helix BioPharma Corp. / Key word(s): Change of Personnel
09.01.2012 08:00
---------------------------------------------------------------------------
AURORA, ON -- (Marketwire) -- 01/09/12 -- Helix BioPharma Corp.
(TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (the 'Company' or
'Helix') announces that Mr. Jack M. Kay has been appointed as
Chairman of the Board. Mr. Kay replaces Dr. Donald H. Segal in this
capacity. Dr. Segal remains as Helix's Chief Executive Officer and a
director of the Company.
Helix is also pleased to announce that Professor Kazimierz
Roszkowski-li has been appointed European Medical
Director, to provide critical oversight and direction for Helix's
upcoming European L-DOS47 clinical program.
Mr. Jack Kay - Chairman of the Board
'I have served as a director of Helix since 2005, and I look forward
to becoming even more involved in the Company as its Chairman,' said
Mr. Kay. 'Having worked in the pharmaceutical industry for over 45
years, and, since 1995, as President of Apotex Inc., I am fully aware
of the challenges involved in bringing new drugs to market. I believe
that Helix's management has done an admirable job in directing both
L-DOS47 and Topical Interferon Alpha-2b through the challenging
clinical trial regulatory approval process, including designing and
undertaking the scientific, analytical and manufacturing work
necessary to do so.
Given the nature of Helix's two lead compounds, this has not been an
easy task, with some setbacks encountered along the way, typical of
the drug development process. Having seen the Helix management team
persevere through and overcome various setbacks, I am impressed with
their creativity, ingenuity and drive that has allowed Helix to
achieve the current stage of development of its two lead drug
candidates. I am excited about Helix's next stage of development and
about continuing to work with the Helix management team and its
proposed new Board of Directors toward realizing our collective
strategic vision to establish Helix as a leading developer of
clinically proven, innovative cancer therapies.'
Mr. Kay has a wealth of experience in the biopharmaceutical and
pharmaceutical sectors. The Apotex Group is the largest
Canadian-owned group of pharmaceutical companies. He has decades of
senior operational, sales and marketing experience within the
pharmaceutical industry. He is a director of several institutional
and charitable organizations, including a director of Baycrest
Hospital, and a past Chairman of the Humber River Regional Hospital,
the International Schizophrenia Foundation, and the Canadian Generic
Pharmaceutical Association. He is also a director of Cangene
Corporation, a TSX traded public biopharmaceutical company.
Professor Kazimierz Roszkowski-li - European Medical
Director
'I, too, look forward to continuing on as part of the Helix team, as
its European Medical Director,' said Professor Kazimierz Roszkowski-
li. 'Stepping down from the Board at the next Annual
General Meeting in order to fulfill this specific role in Helix which
is squarely within my area of expertise in the field of lung cancer
and lung diseases, will enable me to concentrate my efforts for Helix
for the foreseeable future on the further development of L-DOS47. I
have been assisting Helix in this endeavor since becoming a director
of the Company in 2009, and can echo what Jack Kay has said, that
Helix's management has done an admirable job in developing its
L-DOS47 and Topical Interferon Alpha-2b new drug candidates to their
current stage, and I am excited about continuing to work with Helix's
management team in my new capacity.'
Professor Roszkowski-li is an expert in the field of lung
disease and lung cancers, and is a director at the National
Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland,
where he is also head of the clinical department. In addition,
Professor Roszkowski-li consults on lung disease issues
for the Polish Ministry of Health. He received his M.D. from the
Medical Academy in Warsaw and his Ph.D. from the Postgraduate Medical
Center in Warsaw. He is an accomplished researcher with over 230
published papers.
Annual General Meeting
Helix may be facing a contested election for
its board of directors (the 'Board' or the 'Board of Directors') at
its upcoming Annual General Meeting, scheduled for January 30, 2012.
Should this occur, your vote will directly have an impact on the
Company's future direction and the value your investment ultimately
generates.
Shareholders of record as of December 2, 2011 are urged to contact
Kingsdale Shareholder Services Inc. immediately, either by email at
contactus@kingsdaleshareholder.com or by telephone to vote your
shares and protect your investment.
Outside North America, Call Collect:
416-867-2272
North American Toll Free Phone:
1-866-879-7649
About Helix BioPharma Corp.
Helix BioPharma Corp. is a
biopharmaceutical company specializing in the field of cancer
therapy. The Company is actively developing innovative products for
the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its
novel L-DOS47 new drug candidate and its Topical Interferon Alpha-
2b. Helix is listed on the TSX, NYSE Amex and FSE under the symbol
'HBP'.
Disclaimer and Forward-Looking Statements and Risks and
Uncertainties
This News Release contains certain forward-looking
statements and information (collectively, 'forward-looking
statements') within the meaning of applicable securities laws,
including, but not limited to, forward-looking statements regarding
the development of products by Helix for the prevention and treatment
of cancer based on its proprietary technologies; Helix's strategic
vision to establish it as a leading developer of clinically proven,
innovative cancer therapies; Jack Kay and Kazimierz
Roszkwoski-li continuing to work with the Helix
management team; and the possibility that Helix may be facing a
contested election for its board of directors. Forward-looking
statements and information can be identified by forward-looking
terminology such as 'look forward,' 'next,' 'continuing,' 'proposed,'
'foreseeable future,' 'further development,' 'January 30, 2012,' and
similar expressions or variations thereon, or statements that events,
conditions or results 'will,' 'may,' or 'should' occur or be
achieved. Although Helix believes that the expectations reflected in
such forward-looking statements are reasonable, such statements
involve risks and uncertainties, and undue reliance should not be
placed on such statements. Certain material factors or assumptions
are applied in making forward-looking statements, including, but not
limited to, that Helix's proposed directors for election at the
upcoming AGM will be so elected; receipt of necessary additional
funding, strategic partner support and regulatory approvals; the
timely provision of services and performance of contracts by third
parties; and the safety and efficacy of the Company's drug
candidates. Helix's actual results could differ materially from those
reflected in the forward-looking statements as a result of numerous
risks and uncertainties including without limitation, Helix's need
for additional capital, which may not be available and which if not
obtained on a timely basis or in an adequate amount, would have a
material adverse effect on the Company; uncertainty about the outcome
of the Company's upcoming AGM, which may impact on whether Jack Kay
or Kazimierz Roszkowski-Sliz will continue to remain involved with
Helix; uncertainty about whether the Company's products under
development, including L-DOS47 and Topical Interferon Alpha-2b, will
be successfully developed and commercialized and whether clinical
trials will proceed as planned or at all; the risk that clinical
trial results may be negative; insurance and intellectual property
risks; research and development risks; the need for further
regulatory approvals, which may not be obtained; the Company's
dependence on its third-party service providers; upscaling and
manufacturing risks; partnership / strategic alliance risks; the
effect of competition; the risk of technical obsolescence; changes in
business strategy or plans; uncertainty about whether the Company
will be able to realize its strategic vision; and the risk factors
that are discussed under Item 3.D. - 'Risk Factors' in the Company's
latest Form 20-F Annual Report or identified in the Company's other
public filings with the Canadian securities administrators at
www.sedar.com or with the SEC at www.sec.gov. Forward-looking
statements and information are based on the beliefs, assumptions,
opinions and expectations of Helix's management at the time they are
made. Readers are cautioned not to place undue reliance on
forward-looking statements. The forward-looking statements contained
herein are expressly qualified by this cautionary statement and are
made as of the date of this News Release. Helix does not assume any
obligation to update any forward-looking statement or information
should those beliefs, assumptions, opinions or expectations, or other
circumstances change, except as required by law.
News Source: Marketwire
09.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Helix BioPharma Corp.
Canada
Phone:
Fax:
E-mail:
Internet:
ISIN: CA4229101098
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Helix BioPharma Corp. / Key word(s): Change of Personnel
09.01.2012 08:00
---------------------------------------------------------------------------
AURORA, ON -- (Marketwire) -- 01/09/12 -- Helix BioPharma Corp.
(TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (the 'Company' or
'Helix') announces that Mr. Jack M. Kay has been appointed as
Chairman of the Board. Mr. Kay replaces Dr. Donald H. Segal in this
capacity. Dr. Segal remains as Helix's Chief Executive Officer and a
director of the Company.
Helix is also pleased to announce that Professor Kazimierz
Roszkowski-li has been appointed European Medical
Director, to provide critical oversight and direction for Helix's
upcoming European L-DOS47 clinical program.
Mr. Jack Kay - Chairman of the Board
'I have served as a director of Helix since 2005, and I look forward
to becoming even more involved in the Company as its Chairman,' said
Mr. Kay. 'Having worked in the pharmaceutical industry for over 45
years, and, since 1995, as President of Apotex Inc., I am fully aware
of the challenges involved in bringing new drugs to market. I believe
that Helix's management has done an admirable job in directing both
L-DOS47 and Topical Interferon Alpha-2b through the challenging
clinical trial regulatory approval process, including designing and
undertaking the scientific, analytical and manufacturing work
necessary to do so.
Given the nature of Helix's two lead compounds, this has not been an
easy task, with some setbacks encountered along the way, typical of
the drug development process. Having seen the Helix management team
persevere through and overcome various setbacks, I am impressed with
their creativity, ingenuity and drive that has allowed Helix to
achieve the current stage of development of its two lead drug
candidates. I am excited about Helix's next stage of development and
about continuing to work with the Helix management team and its
proposed new Board of Directors toward realizing our collective
strategic vision to establish Helix as a leading developer of
clinically proven, innovative cancer therapies.'
Mr. Kay has a wealth of experience in the biopharmaceutical and
pharmaceutical sectors. The Apotex Group is the largest
Canadian-owned group of pharmaceutical companies. He has decades of
senior operational, sales and marketing experience within the
pharmaceutical industry. He is a director of several institutional
and charitable organizations, including a director of Baycrest
Hospital, and a past Chairman of the Humber River Regional Hospital,
the International Schizophrenia Foundation, and the Canadian Generic
Pharmaceutical Association. He is also a director of Cangene
Corporation, a TSX traded public biopharmaceutical company.
Professor Kazimierz Roszkowski-li - European Medical
Director
'I, too, look forward to continuing on as part of the Helix team, as
its European Medical Director,' said Professor Kazimierz Roszkowski-
li. 'Stepping down from the Board at the next Annual
General Meeting in order to fulfill this specific role in Helix which
is squarely within my area of expertise in the field of lung cancer
and lung diseases, will enable me to concentrate my efforts for Helix
for the foreseeable future on the further development of L-DOS47. I
have been assisting Helix in this endeavor since becoming a director
of the Company in 2009, and can echo what Jack Kay has said, that
Helix's management has done an admirable job in developing its
L-DOS47 and Topical Interferon Alpha-2b new drug candidates to their
current stage, and I am excited about continuing to work with Helix's
management team in my new capacity.'
Professor Roszkowski-li is an expert in the field of lung
disease and lung cancers, and is a director at the National
Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland,
where he is also head of the clinical department. In addition,
Professor Roszkowski-li consults on lung disease issues
for the Polish Ministry of Health. He received his M.D. from the
Medical Academy in Warsaw and his Ph.D. from the Postgraduate Medical
Center in Warsaw. He is an accomplished researcher with over 230
published papers.
Annual General Meeting
Helix may be facing a contested election for
its board of directors (the 'Board' or the 'Board of Directors') at
its upcoming Annual General Meeting, scheduled for January 30, 2012.
Should this occur, your vote will directly have an impact on the
Company's future direction and the value your investment ultimately
generates.
Shareholders of record as of December 2, 2011 are urged to contact
Kingsdale Shareholder Services Inc. immediately, either by email at
contactus@kingsdaleshareholder.com or by telephone to vote your
shares and protect your investment.
Outside North America, Call Collect:
416-867-2272
North American Toll Free Phone:
1-866-879-7649
About Helix BioPharma Corp.
Helix BioPharma Corp. is a
biopharmaceutical company specializing in the field of cancer
therapy. The Company is actively developing innovative products for
the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its
novel L-DOS47 new drug candidate and its Topical Interferon Alpha-
2b. Helix is listed on the TSX, NYSE Amex and FSE under the symbol
'HBP'.
Disclaimer and Forward-Looking Statements and Risks and
Uncertainties
This News Release contains certain forward-looking
statements and information (collectively, 'forward-looking
statements') within the meaning of applicable securities laws,
including, but not limited to, forward-looking statements regarding
the development of products by Helix for the prevention and treatment
of cancer based on its proprietary technologies; Helix's strategic
vision to establish it as a leading developer of clinically proven,
innovative cancer therapies; Jack Kay and Kazimierz
Roszkwoski-li continuing to work with the Helix
management team; and the possibility that Helix may be facing a
contested election for its board of directors. Forward-looking
statements and information can be identified by forward-looking
terminology such as 'look forward,' 'next,' 'continuing,' 'proposed,'
'foreseeable future,' 'further development,' 'January 30, 2012,' and
similar expressions or variations thereon, or statements that events,
conditions or results 'will,' 'may,' or 'should' occur or be
achieved. Although Helix believes that the expectations reflected in
such forward-looking statements are reasonable, such statements
involve risks and uncertainties, and undue reliance should not be
placed on such statements. Certain material factors or assumptions
are applied in making forward-looking statements, including, but not
limited to, that Helix's proposed directors for election at the
upcoming AGM will be so elected; receipt of necessary additional
funding, strategic partner support and regulatory approvals; the
timely provision of services and performance of contracts by third
parties; and the safety and efficacy of the Company's drug
candidates. Helix's actual results could differ materially from those
reflected in the forward-looking statements as a result of numerous
risks and uncertainties including without limitation, Helix's need
for additional capital, which may not be available and which if not
obtained on a timely basis or in an adequate amount, would have a
material adverse effect on the Company; uncertainty about the outcome
of the Company's upcoming AGM, which may impact on whether Jack Kay
or Kazimierz Roszkowski-Sliz will continue to remain involved with
Helix; uncertainty about whether the Company's products under
development, including L-DOS47 and Topical Interferon Alpha-2b, will
be successfully developed and commercialized and whether clinical
trials will proceed as planned or at all; the risk that clinical
trial results may be negative; insurance and intellectual property
risks; research and development risks; the need for further
regulatory approvals, which may not be obtained; the Company's
dependence on its third-party service providers; upscaling and
manufacturing risks; partnership / strategic alliance risks; the
effect of competition; the risk of technical obsolescence; changes in
business strategy or plans; uncertainty about whether the Company
will be able to realize its strategic vision; and the risk factors
that are discussed under Item 3.D. - 'Risk Factors' in the Company's
latest Form 20-F Annual Report or identified in the Company's other
public filings with the Canadian securities administrators at
www.sedar.com or with the SEC at www.sec.gov. Forward-looking
statements and information are based on the beliefs, assumptions,
opinions and expectations of Helix's management at the time they are
made. Readers are cautioned not to place undue reliance on
forward-looking statements. The forward-looking statements contained
herein are expressly qualified by this cautionary statement and are
made as of the date of this News Release. Helix does not assume any
obligation to update any forward-looking statement or information
should those beliefs, assumptions, opinions or expectations, or other
circumstances change, except as required by law.
News Source: Marketwire
09.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Helix BioPharma Corp.
Canada
Phone:
Fax:
E-mail:
Internet:
ISIN: CA4229101098
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------